PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452GlobeNewsWire • 01/10/20
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of TicagrelorGlobeNewsWire • 10/15/19
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of TicagrelorGlobeNewsWire • 09/24/19
Pharmacodynamics Evaluation of PhaseBio’s Novel Ticagrelor Reversal Agent Presented at ESC Congress 2019GlobeNewsWire • 09/03/19
PhaseBio's Latest FDA Designation Moves It One Step Closer To Potential ApprovalSeeking Alpha • 04/17/19
PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agentMarket Watch • 03/18/19